Wenda Ye Selected Research

ASTX-660

1/2020	ASTX660, an antagonist of cIAP1/2 and XIAP, increases antigen processing machinery and can enhance radiation-induced immunogenic cell death in preclinical models of head and neck cancer.
11/2019	Dual Antagonist of cIAP/XIAP ASTX660 Sensitizes HPV- and HPV+ Head and Neck Cancers to TNFα, TRAIL, and Radiation Therapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Wenda Ye Research Topics

Disease

4	Head and Neck Neoplasms (Head and Neck Cancer) 01/2020 - 01/2019
3	Squamous Cell Carcinoma of Head and Neck 01/2020 - 01/2019
3	Neoplasms (Cancer) 01/2020 - 01/2019
1	Mouth Neoplasms (Oral Cancer) 01/2019
1	Pain (Aches) 01/2019
1	Hypersensitivity (Allergy) 01/2019
1	Ischemia 01/2018

Drug/Important Bio-Agent (IBA)

2	ASTX-660IBA 01/2020 - 11/2019
2	Inhibitor of Apoptosis ProteinsIBA 01/2020 - 11/2019
1	HLA-A Antigens (HLA-A)IBA 01/2020
1	AntigensIBA 01/2020
1	LigandsIBA 11/2019
1	Proteins (Proteins, Gene)FDA Link 11/2019
1	pembrolizumabIBA 03/2019
1	propylene diquat (PDQ(+))IBA 01/2019
1	PlatinumIBA 01/2019
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2019
1	Cisplatin (Platino)FDA LinkGeneric 01/2019
1	Pharmaceutical PreparationsIBA 01/2019

Therapy/Procedure

1	Radiotherapy 11/2019
1	Therapeutics 01/2019
1	Drug Therapy (Chemotherapy) 01/2019
1	Immunotherapy 01/2019
1	Nephrectomy 01/2018